Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TMA is associated with low VEGF expression and end-stage renal disease in patients with diabetic nephropathy..
|
29249229 |
2018 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Soluble Flt-1 (sFlt-1) is the endogenous inhibitor of VEGF, and recently genetic overexpression of sFlt-1 in the podocyte was shown to be protective in murine diabetic nephropathy.
|
20015944 |
2010 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients.
|
11499563 |
2001 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined the relationship between VEGF and its isoforms and the severity of diabetic nephropathy in type 2 diabetes.
|
15191350 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry showed both increased TRPC6 channel protein and VEGF receptor type 2 (VEGFR-2) protein in podocytes from patients with diabetic nephropathy compared to control subjects.
|
21868397 |
2012 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the possible association of the VEGF gene polymorphisms with diabetic nephropathy and retinopathy in type 2 diabetes patients.
|
17121786 |
2007 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In diabetes, over-production of NO might play a role in the development of diabetic nephropathy, while reduced NO production may be related to the development of diabetic retinopathy and neuropathy, where VEGF (vascular endothelial growth factor) levels are increased in a counter regulatory manner.
|
20565248 |
2010 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
|
30389746 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because VEGF is known to be associated with the pathogenesis of some diseases, such as diabetic nephropathy, renal tumor and polycystic kidney disease, the study about the role of VEGF is going to be a target for disease control.
|
12872442 |
2003 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, we have hypothesized that uncoupling of VEGF with endothelial NO can be a mechanism by which VEGF causes diabetic nephropathy.
|
18926584 |
2008 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining for VEGF-A and EGF also showed a reduced expression in DN.
|
17475821 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a dimeric glycoprotein that plays a crucial role in microvascular complications of diabetes, including diabetic nephropathy.
|
20501654 |
2010 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
LHGDN |
Podocyte-derived vascular endothelial growth factor (VEGF), a permeability and angiogenic factor whose expression is also increased in animal models of diabetic kidney disease, appears to act in a novel autocrine signaling mode to induce the podocytopathy of diabetes, especially the genesis of albuminuria.
|
18842317 |
2008 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the VEGF-1499T allele, or an allele in linkage disequilibrium with this allele, is associated with susceptibility to diabetic nephropathy in the Irish population.
|
17616354 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
[Effects of valsartan on the renal vascular endothelial growth factor and its receptor flk-1 of diabetic rats].
|
18630688 |
2008 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that polymorphisms in the promoter region of the VEGF gene together with the ALR2 may be associated with the pathogenesis of diabetic nephropathy.
|
12505748 |
2003 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors.
|
15031673 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, our study aims to investigate protective effect of hUSC exosome along with microRNA-16-5p (miR-16-5p) on podocytes in DN via vascular endothelial growth factor A (VEGFA).
|
31568645 |
2019 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Considering the putative contribution of VEGF to T2D and its complications, we aimed to assess the effect of these VEGF-related SNPs on the risk of T2D, nephropathy and retinopathy, as well as on variation in related traits.SNPs were genotyped in several case-control studies: French and Danish T2D studies (N(cases) = 6,920-N(controls) = 3,875 and N(cases) = 3,561-N(controls) = 2,623; respectively), two French studies one for diabetic nephropathy (N(cases) = 1,242-N(controls) = 860) and the other for diabetic retinopathy (N(cases) = 1,336-N(controls) = 1,231).
|
23405237 |
2013 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that polymorphisms in the promoter region of the VEGF gene together with the ALR2 may be associated with the pathogenesis of diabetic nephropathy.
|
12505748 |
2003 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the effect of Pueraria tuberosa extract (PTY-2r) on the expression of HIF-1α, VEGF and nephrin in streptozotocin (STZ) induced diabetic nephropathy (DN).
|
28648975 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that glomerular LRG1 expression is increased earlier than VEGF expression under conditions of pathological angiogenesis in the early stage of diabetic nephropathy.
|
30515388 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The involvement of VEGF-A as well as the therapeutic efficacy of angiogenesis inhibitors in diabetic nephropathy have been reported.
|
21228103 |
2011 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we investigated the association of these VEGF polymorphisms with proliferative diabetic retinopathy and diabetic nephropathy.
|
14988276 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
LHGDN |
Vascular endothelial growth factor in diabetic nephropathy.
|
14610338 |
2003 |